Diclofenac sodium transdermal - NAL Pharma
Alternative Names: NAL 1219Latest Information Update: 24 Mar 2025
At a glance
- Originator NAL Pharma
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Pain
Most Recent Events
- 24 Mar 2025 Diclofenac sodium transdermal is still in clinical trials for pain (Transdermal, Patch) (NAL Pharma pipeline, March 2025)
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Pain in Unknown (Transdermal, Patch)
- 26 May 2022 Diclofenac sodium transdermal is still in clinical trials for pain (NAL Pharma pipeline, May 2022)